China Aoxing Pharmaceutical Company (AXN) 0.25 $AXN
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSE MKT LLC
Marketwire - Wed Aug 06, 6:15AM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide:
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension and Additional Notice of Noncompliance From NYSE MKT LLC
Marketwire - Tue Mar 04, 4:30PM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced on October 30, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended, and (b) is not in compliance with Section 1003(a)(iv) of the Company Guide since it has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the NYSE MKT, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. Aoxing Pharma further announced on December 4, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Quarterly Report on Form 10-Q for the period ended September 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(ii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $4,000,000 at September 30, 2013 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years ended June 30, 2013.
Aoxing Pharmaceutical Company Inc posts lower net loss of USD1.918m for fiscal 2014 second quarter
M2 - Thu Feb 20, 9:06AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) on Wednesday reported a net loss of USD1.918m for its fiscal 2014 second quarter ended 31 December 2013.
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for Second Quarter of 2014 Fiscal Year
Marketwire - Wed Feb 19, 11:15AM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 19, 2014.
Why You Need to Pay Attention to Cambrex Corporation. (CBM) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:59AM CST
One company that should be on your radar is Cambrex Corporation that witnessed its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Strong Buy.
An Artful Way to Fight Dystonia
PR Newswire - Tue Jan 28, 7:30AM CST
Imagine a potentially debilitating neuromuscular disease that is relatively unknown, yet affects a half-million Americans of various ages, and, despite ongoing research, so far has no known cure. In addition, treatments are currently limited and carry significant side effects and risk. Would this qualify as a disease worthy of public awareness and continued research in the hopes of finding a cure? Thirteen-year-old entrepreneur Jared Shadkin believes that it is, and he is using the proceeds from the sale of his art to fund organizations dedicated to Dystonia awareness and research.
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base.
OTC Signal Daily Stock Watch - Aoxing Pharmaceutical Company, Inc (NYSE: AXN)
WorldStockWire - Wed Sep 04, 4:45PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
PR Newswire - Wed May 15, 3:21PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and nine month periods ended March 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May 15, 2013.
DAN, VRS, TEAR, AXN, DBB, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue May 14, 5:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Dana Holding Corp (NYSE
AN), Verso Paper Corp (NYSE:VRS), Tearlab Corp (NASDAQ:TEAR), Aoxing Pharmaceutical Company Inc (AMEX:AXN), PowerShares DB Base Metals Fund (NYSE BB), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
WEALTHMAKERS.COM Issues Bullish Research Reports on ADS, AXN, EGN, ETR, GABC, GTS
M2 - Fri Mar 29, 10:47AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Alliance Data Systems Corp (NYSE:ADS), Aoxing Pharmaceutical Company Inc (AMEX:AXN), Engineeringcom Inc (NYSE:EGN), ENTERGY CORP (NYSE:ETR), German American Bancorp Inc (NASDAQ:GABC), Triple S Management Corp (NYSE:GTS)
Aoxing Pharmaceutical Company Inc reports net losses of USD3.136m for Q2 fiscal 2013
M2 - Tue Feb 19, 8:25AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) announced on Monday its net losses of USD3.136m for the three month period ended 31 December 2012.
Aoxing Pharmaceutical posts net loss of USD3.13m for Q2 fiscal 2013
M2 - Mon Feb 18, 6:48AM CST
Speciality pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT: AXN) on Friday reported a net loss of USD3.135m for the second quarter of fiscal 2013, ended 31 December 2013.
Aoxing Pharmaceutical Company Inc's losses from operations widens to USD2.35m in Q2 fiscal 2013
M2 - Mon Feb 18, 6:39AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) stated on Friday its losses from operations of USD2.35m for the three month period ended 31 December 2012.
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSE MKT LLC
Marketwire - Wed Aug 06, 6:15AM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide: Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension and Additional Notice of Noncompliance From NYSE MKT LLC
Marketwire - Tue Mar 04, 4:30PM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced on October 30, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended, and (b) is not in compliance with Section 1003(a)(iv) of the Company Guide since it has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the NYSE MKT, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. Aoxing Pharma further announced on December 4, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Quarterly Report on Form 10-Q for the period ended September 30, 2013, Aoxing Pharma (a) is not in compliance with Section 1003(a)(ii) of the NYSE MKT Company Guide since it reported stockholders' equity of less than $4,000,000 at September 30, 2013 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years ended June 30, 2013. Aoxing Pharmaceutical Company Inc posts lower net loss of USD1.918m for fiscal 2014 second quarter
M2 - Thu Feb 20, 9:06AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) on Wednesday reported a net loss of USD1.918m for its fiscal 2014 second quarter ended 31 December 2013.
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for Second Quarter of 2014 Fiscal Year
Marketwire - Wed Feb 19, 11:15AM CST
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 19, 2014. Why You Need to Pay Attention to Cambrex Corporation. (CBM) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:59AM CST
One company that should be on your radar is Cambrex Corporation that witnessed its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Strong Buy.
An Artful Way to Fight Dystonia
PR Newswire - Tue Jan 28, 7:30AM CST
Imagine a potentially debilitating neuromuscular disease that is relatively unknown, yet affects a half-million Americans of various ages, and, despite ongoing research, so far has no known cure. In addition, treatments are currently limited and carry significant side effects and risk. Would this qualify as a disease worthy of public awareness and continued research in the hopes of finding a cure? Thirteen-year-old entrepreneur Jared Shadkin believes that it is, and he is using the proceeds from the sale of his art to fund organizations dedicated to Dystonia awareness and research.
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base. OTC Signal Daily Stock Watch - Aoxing Pharmaceutical Company, Inc (NYSE: AXN)
WorldStockWire - Wed Sep 04, 4:45PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
PR Newswire - Wed May 15, 3:21PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and nine month periods ended March 31, 2013. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May 15, 2013. DAN, VRS, TEAR, AXN, DBB, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue May 14, 5:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Dana Holding Corp (NYSE
AN), Verso Paper Corp (NYSE:VRS), Tearlab Corp (NASDAQ:TEAR), Aoxing Pharmaceutical Company Inc (AMEX:AXN), PowerShares DB Base Metals Fund (NYSE BB), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: WEALTHMAKERS.COM Issues Bullish Research Reports on ADS, AXN, EGN, ETR, GABC, GTS
M2 - Fri Mar 29, 10:47AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Alliance Data Systems Corp (NYSE:ADS), Aoxing Pharmaceutical Company Inc (AMEX:AXN), Engineeringcom Inc (NYSE:EGN), ENTERGY CORP (NYSE:ETR), German American Bancorp Inc (NASDAQ:GABC), Triple S Management Corp (NYSE:GTS)
Aoxing Pharmaceutical Company Inc reports net losses of USD3.136m for Q2 fiscal 2013
M2 - Tue Feb 19, 8:25AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) announced on Monday its net losses of USD3.136m for the three month period ended 31 December 2012.
Aoxing Pharmaceutical posts net loss of USD3.13m for Q2 fiscal 2013
M2 - Mon Feb 18, 6:48AM CST
Speciality pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT: AXN) on Friday reported a net loss of USD3.135m for the second quarter of fiscal 2013, ended 31 December 2013.
Aoxing Pharmaceutical Company Inc's losses from operations widens to USD2.35m in Q2 fiscal 2013
M2 - Mon Feb 18, 6:39AM CST
Pharmaceutical company Aoxing Pharmaceutical Company Inc (NYSE MKT:AXN) stated on Friday its losses from operations of USD2.35m for the three month period ended 31 December 2012.
